EIF3H and non-small cell lung carcinoma: More importantly, eIF3h and Myc co-amplification markedly improve the response and survival of NSCLC patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor such as gefitinib [119].